MX343525B - Composiciones inmunomoduladoras y metodos de uso de las mismas. - Google Patents

Composiciones inmunomoduladoras y metodos de uso de las mismas.

Info

Publication number
MX343525B
MX343525B MX2015004908A MX2015004908A MX343525B MX 343525 B MX343525 B MX 343525B MX 2015004908 A MX2015004908 A MX 2015004908A MX 2015004908 A MX2015004908 A MX 2015004908A MX 343525 B MX343525 B MX 343525B
Authority
MX
Mexico
Prior art keywords
glucans
certain embodiments
methods
conjugated
immune response
Prior art date
Application number
MX2015004908A
Other languages
English (en)
Inventor
R Fink Gerald
Rubin-Bejerano Ifat
Original Assignee
Immunexcite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunexcite Inc filed Critical Immunexcite Inc
Publication of MX343525B publication Critical patent/MX343525B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a un kit de diagnóstico para medir niveles de IgG1, IgG2, IgG3 e IgG4, y con ello determinar sensibilidad de un sujeto que ha sido expuesto a glucanos ambientales a una composición farmacéutica que comprende ß-1-6 - glucano, caracterizado porque comprende: (i) una composición que comprende ß-1-6 - glucano que corresponde a o es un fragmento de, o es altamente homólogo al glucano en la composición farmacéutica para la cual se está determinando sensibilidad; y (ii) reactivos para detectar anticuerpos de IgG1 IgG2, IgG3 e IgG4 unidos al ß-1-6 - glucano de etapa (i) en una muestra de sangre.
MX2015004908A 2008-04-29 2009-04-29 Composiciones inmunomoduladoras y metodos de uso de las mismas. MX343525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7143708P 2008-04-29 2008-04-29
PCT/US2009/042117 WO2009134891A2 (en) 2008-04-29 2009-04-29 Immunomodulating compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX343525B true MX343525B (es) 2016-11-09

Family

ID=41255756

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010011788A MX2010011788A (es) 2008-04-29 2009-04-29 Composiciones inmunomoduladoras y metodos de uso de las mismas.
MX2015004908A MX343525B (es) 2008-04-29 2009-04-29 Composiciones inmunomoduladoras y metodos de uso de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010011788A MX2010011788A (es) 2008-04-29 2009-04-29 Composiciones inmunomoduladoras y metodos de uso de las mismas.

Country Status (11)

Country Link
US (2) US8617823B2 (es)
EP (1) EP2283358B1 (es)
JP (2) JP2011519049A (es)
CN (1) CN102119332A (es)
AU (1) AU2009243094B2 (es)
BR (1) BRPI0912703A2 (es)
CA (1) CA2760044A1 (es)
ES (1) ES2542066T3 (es)
IL (1) IL208946A0 (es)
MX (2) MX2010011788A (es)
WO (1) WO2009134891A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
JP6082174B2 (ja) 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US20100111872A1 (en) * 2008-11-06 2010-05-06 University Of Saskatchewan System and method for modulating and optimizing immunotherapy
TWI711610B (zh) 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
WO2011063395A2 (en) * 2009-11-23 2011-05-26 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012139089A2 (en) 2011-04-08 2012-10-11 The General Hospital Corporation Fungal-derived carbohydrate-conjugated scaffold
ES2869181T3 (es) * 2011-06-03 2021-10-25 Hibercell Inc Métodos y preparaciones de beta-glucano opsonizado
KR20150013206A (ko) * 2012-04-30 2015-02-04 바이오테라, 인크. β-글루칸 면역요법을 위한 조성물 및 방법
CA2875331C (en) * 2012-06-05 2022-11-29 Nestec S.A. Methods for diagnosing chronic valvular disease
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN102901831B (zh) * 2012-10-25 2015-01-14 杭州宝康亿富生物科技有限公司 一种免疫调节多糖生物活性检测方法
WO2014159614A1 (en) * 2013-03-14 2014-10-02 Flow Pharma, Inc. Adjuvant and antigen particle formulation
CN104341409B (zh) * 2013-07-31 2017-11-28 北京勤邦生物技术有限公司 一种噻苯咪唑半抗原制备方法及其应用
BR112016010025A2 (pt) 2013-11-11 2017-12-05 Chugai Pharmaceutical Co Ltd molécula de ligação de antígeno contendo região variável de anticorpo modificado
CA2932192C (en) 2013-12-05 2020-10-06 Biothera, Inc. .beta.-glucan assay methods
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
AU2015255823A1 (en) 2014-05-08 2016-11-10 Immunexcite, Inc. Immunomodulating beta-1,6-D-glucans
CN104072630B (zh) * 2014-07-11 2016-04-06 合肥工业大学 一种黄山石耳冷致凝胶多糖及其制备方法
US20170216297A1 (en) 2014-07-28 2017-08-03 Technische Universitaet Dresden Efficient inhibition of hsp27
EP3247408A4 (en) * 2015-01-20 2018-08-22 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
CN105879006A (zh) * 2016-02-01 2016-08-24 四川好医生攀西药业有限责任公司 一种治疗糖尿病足溃疡的药物组合物及其制备方法和应用
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
US11512126B2 (en) 2016-05-31 2022-11-29 Mogam Institute For Biomedicak Research AB6 family designer ligands of TGF-β superfamily
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
EP3279664A1 (en) * 2016-08-05 2018-02-07 Universität zu Köln Means and methods for detecting beta-1,6-glucan
WO2018024827A1 (en) * 2016-08-05 2018-02-08 Universität Zu Köln Means and methods for detecting beta-1,6-glucan
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US11865135B2 (en) 2016-12-07 2024-01-09 Innate Biotherapeutics, Llc ß-1,6-glucan therapeutic antibody conjugates
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
KR102205829B1 (ko) 2017-06-14 2021-01-21 기초과학연구원 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US10946038B2 (en) * 2017-08-09 2021-03-16 Case Western Reserve University Cancer treatment using beta-(1-3)-(1-4)-glucan
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN113189315B (zh) * 2021-04-13 2024-01-23 山东省医疗器械产品质量检验中心 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法
WO2024077042A2 (en) * 2022-10-05 2024-04-11 Onspira Therapeutics, Inc. Il-1 receptor antagonist treatment for neutrophilic lung disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590181A (en) * 1982-12-20 1986-05-20 Board Of Regents Of The University Of Nebraska Synthetic immunoregulators and methods of use and preparation
US5480642A (en) * 1982-12-20 1996-01-02 The Board Of Regents Of The University Of Nebraska Synthetic immunoreglators, and methods of use and preparation
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
SE0203099D0 (en) * 2002-10-21 2002-10-21 A & Science Ab Publ Diagnosis of candidiasis and candidemia or invasive candida infection
WO2007033315A1 (en) 2005-09-14 2007-03-22 Whitehead Institute For Biomedical Research Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan
BRPI0711572A2 (pt) * 2006-04-17 2011-11-16 Schering Plough Ltd organismos recombinantes atenuados de clostridium e vacinas
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP6082174B2 (ja) 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法

Also Published As

Publication number Publication date
WO2009134891A2 (en) 2009-11-05
JP2015004690A (ja) 2015-01-08
EP2283358A4 (en) 2011-09-07
JP5959589B2 (ja) 2016-08-02
US20110177532A1 (en) 2011-07-21
ES2542066T3 (es) 2015-07-30
US20140308238A1 (en) 2014-10-16
JP2011519049A (ja) 2011-06-30
BRPI0912703A2 (pt) 2017-06-13
WO2009134891A3 (en) 2010-02-18
CA2760044A1 (en) 2009-11-05
AU2009243094B2 (en) 2015-02-12
AU2009243094A1 (en) 2009-11-05
US8617823B2 (en) 2013-12-31
IL208946A0 (en) 2011-01-31
EP2283358B1 (en) 2015-04-22
CN102119332A (zh) 2011-07-06
US9005903B2 (en) 2015-04-14
MX2010011788A (es) 2011-05-30
EP2283358A2 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
MX343525B (es) Composiciones inmunomoduladoras y metodos de uso de las mismas.
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
NL300914I2 (nl) Atezolizumab
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
WO2013063419A3 (en) A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
CA2856895C (en) Anti-pd-l1 antibodies and uses thereof
WO2008019199A8 (en) FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
EP3421488A3 (en) Multispecific antigen-binding molecules and uses thereof
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
EA202090338A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
JO2576B1 (en) Antibodies
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
BRPI1014544B8 (pt) anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
MY165618A (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
WO2008086182A3 (en) Use of gene signatures to design novel cancer treatment regimens
WO2008156763A3 (en) Human neutralizing monoclonal antibodies to h5n1 influenza a virus
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
WO2012006341A3 (en) Anti-ron antibodies